Pacific Biosciences of California Stock News

Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday. Aeglea BioTherapeutics, Inc. (NASDAQ:

Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 145% to $38.45 on continued volatility following the company's IPO on Thursday. Volcon, Inc. (NASDAQ: VLCN) gained 51% to $2.7899 after t

Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. Twin Vee Powercats Co. (NASDAQ: VEEE) shares cl

Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year. Unity Biotechnology, Inc. (NYSE: UBX) jumped 70% to $1.4492 af

Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering. T2 Biosystems, Inc. (NASDAQ: TTOO) s

Absci Corporation (NASDAQ: ABSI) jumped 38.8% to $5.83 after the company reported a narrower Q2 loss. Veru Inc (NASDAQ: VERU) shares gained 30.5% to $15.36 after the company reported Q3 earnings res

Source: motorolka / Shutterstock.com Various biotech stocks are in focus today, but Pacific Biosciences (NASDAQ: PACB ) is one of the more notable names investors are watching right now. At the time

Cathie Wood's exchange-traded funds (ETFs) received a breath of fresh air this week. The ARK Innovation ETF (NYSEMKT: ARKK ) ended the period up over 12%.

Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund. For A

PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.

The consensus price target hints at a 261.4% upside potential for Pacific Biosciences (PACB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni

PACB earnings call for the period ending June 30, 2022.

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Todd Friedman – Director of Investor Relations Christian Henry

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?